Log in

NASDAQ:BSGMBioSig Technologies Stock Price, Forecast & News

-0.10 (-0.91 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $10.91
50-Day Range
MA: $7.71
52-Week Range
Now: $10.91
Volume419,000 shs
Average Volume603,707 shs
Market Capitalization$284.85 million
P/E RatioN/A
Dividend YieldN/A
BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:BSGM



Sales & Book Value

Annual SalesN/A
Book Value$0.53 per share


Net Income$-34,060,000.00


Market Cap$284.85 million
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive BSGM News and Ratings via Email

Sign-up to receive the latest news and ratings for BSGM and its competitors with MarketBeat's FREE daily newsletter.

BioSig Technologies (NASDAQ:BSGM) Frequently Asked Questions

How has BioSig Technologies' stock been impacted by COVID-19 (Coronavirus)?

BioSig Technologies' stock was trading at $3.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BSGM shares have increased by 247.5% and is now trading at $10.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioSig Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSig Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioSig Technologies.

When is BioSig Technologies' next earnings date?

BioSig Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for BioSig Technologies.

How were BioSig Technologies' earnings last quarter?

BioSig Technologies Inc (NASDAQ:BSGM) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.22. View BioSig Technologies' earnings history.

What price target have analysts set for BSGM?

1 Wall Street analysts have issued 12-month price targets for BioSig Technologies' stock. Their forecasts range from $9.00 to $9.00. On average, they expect BioSig Technologies' share price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 17.5%. View analysts' price targets for BioSig Technologies.

Has BioSig Technologies been receiving favorable news coverage?

News stories about BSGM stock have trended very positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioSig Technologies earned a news impact score of 4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutBioSig Technologies.

Are investors shorting BioSig Technologies?

BioSig Technologies saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 2,460,000 shares, a drop of 8.9% from the April 30th total of 2,700,000 shares. Based on an average daily volume of 763,800 shares, the short-interest ratio is presently 3.2 days. Approximately 12.7% of the shares of the company are sold short. View BioSig Technologies' Current Options Chain.

Who are some of BioSig Technologies' key competitors?

What other stocks do shareholders of BioSig Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSig Technologies investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Roku (ROKU), Amarin (AMRN), Novavax (NVAX), Pfizer (PFE), Intel (INTC), Micron Technology (MU), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Who are BioSig Technologies' key executives?

BioSig Technologies' management team includes the following people:
  • Mr. Kenneth L. Londoner M.B.A., MBA, Founder, CEO & Exec. Chairman (Age 51)
  • Mr. Steven Chaussy, Chief Financial Officer (Age 65)
  • Ms. Lora Mikolaitis, VP of Admin. (Age 46)
  • Mrs. Tiffini Wittwer, Chief Regulatory & Compliance Officer
  • Mr. John Kowalski, VP of Sales

What is BioSig Technologies' stock symbol?

BioSig Technologies trades on the NASDAQ under the ticker symbol "BSGM."

Who are BioSig Technologies' major shareholders?

BioSig Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.43%), State Street Corp (1.07%), Zeke Capital Advisors LLC (0.87%), Geode Capital Management LLC (0.86%), Cambridge Investment Research Advisors Inc. (0.41%) and Wells Fargo & Company MN (0.14%). Company insiders that own BioSig Technologies stock include Kenneth L Londoner, Martha Pease, Samuel E Navarro and Steve Chaussy. View institutional ownership trends for BioSig Technologies.

Which institutional investors are selling BioSig Technologies stock?

BSGM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, and IHT Wealth Management LLC. View insider buying and selling activity for BioSig Technologies.

Which institutional investors are buying BioSig Technologies stock?

BSGM stock was bought by a variety of institutional investors in the last quarter, including Zeke Capital Advisors LLC, Parametric Portfolio Associates LLC, Geode Capital Management LLC, BlackRock Inc., Cambridge Investment Research Advisors Inc., Wells Fargo & Company MN, Advisor Group Holdings Inc., and State Street Corp. Company insiders that have bought BioSig Technologies stock in the last two years include Kenneth L Londoner, Martha Pease, Samuel E Navarro, and Steve Chaussy. View insider buying and selling activity for BioSig Technologies.

How do I buy shares of BioSig Technologies?

Shares of BSGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioSig Technologies' stock price today?

One share of BSGM stock can currently be purchased for approximately $10.91.

How big of a company is BioSig Technologies?

BioSig Technologies has a market capitalization of $284.85 million. BioSig Technologies employs 20 workers across the globe.

What is BioSig Technologies' official website?

The official website for BioSig Technologies is www.biosig.com.

How can I contact BioSig Technologies?

BioSig Technologies' mailing address is 54 WILTON ROAD, WESTPORT CT, 06880. The company can be reached via phone at 203-409-5444 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.